Market Overview

UPDATE: Goldman Sachs Upgrades Varian Medical Systems to Neutral; Downside Less Evident Now

Share:
Related VAR
Advanced Radiotherapy Treatments Planned Using Varian's RapidPlan Commence in Australia
Studies Show that RapidArc Radiosurgery is a Viable, Time Efficient Way to Treat Multiple Brain Metastases

Goldman Sachs upgraded Varian Medical Systems (NYSE: VAR) from Sell to Neutral and raised the price target from $62.00 to $79.00.

Goldman Sachs commented, "We upgrade shares of Varian Medical Systems (VAR) to Neutral from Sell, as we see business fundamentals stabilizing and consensus estimates now look reasonable. Our Sell thesis on the stock has largely played out with annual Street numbers coming down 8%-10% since 2010. While Varian's core US/EU markets face pressure, the degree of that pressure looks to be abating (predominantly in the US). Near-term competitive dynamics also look more manageable. Given the rebasing of expectations, we see the risk/reward as more balanced."

Varian Medical Systems closed at $72.01 on Wednesday.

Latest Ratings for VAR

DateFirmActionFromTo
Apr 2015JP MorganDowngradesOverweightNeutral
Apr 2015JP MorganDowngradesOverweightNeutral
Jan 2015JefferiesMaintainsBuy

View More Analyst Ratings for VAR
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Upgrades Analyst Ratings

 

Related Articles (VAR)

View Comments and Join the Discussion!

Get Benzinga's Newsletters